Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 114 Breast Neoplasms 79 Neoplasms 74 Neoplasm Metastasis 63 Colorectal Neoplasms 62 Prostatic Neoplasms 57 Recurrence 56 Pancreatic Neoplasms 55 Leukemia, Myeloid, Acute 55 Ovarian Neoplasms 53 Multiple Myeloma 50 Melanoma 39 Glioblastoma 38 Squamous Cell Carcinoma of Head and Neck 33 Lung Neoplasms 33 Triple Negative Breast Neoplasms 31 Lymphoma, Non-Hodgkin 30 Endometrial Neoplasms 30 Precursor Cell Lymphoblastic Leukemia-Lymphoma 29 Lymphoma 27 Carcinoma, Renal Cell 27 Lymphoma, Large B-Cell, Diffuse 26 Stomach Neoplasms 25 Lymphoma, B-Cell 25 Carcinoma, Hepatocellular 24 Advanced Solid Tumor 24 Small Cell Lung Carcinoma 23 Leukemia, Lymphocytic, Chronic, B-Cell 23 Burkitt Lymphoma 23 Brain Neoplasms 23

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Cancer Recurrent × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡